These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 20043021)

  • 1. Trial watch: Antisense agent reduces LDL-cholesterol levels in high-risk patients.
    Nat Rev Drug Discov; 2010 Jan; 9(1):10. PubMed ID: 20043021
    [No Abstract]   [Full Text] [Related]  

  • 2. Two new drugs for homozygous familial hyperchelesterolemia.
    Med Lett Drugs Ther; 2013 Apr; 55(1413):25-7. PubMed ID: 23545581
    [No Abstract]   [Full Text] [Related]  

  • 3. Mipomersen as a potential adjunctive therapy for hypercholesterolemia.
    Patel N; Hegele RA
    Expert Opin Pharmacother; 2010 Oct; 11(15):2569-72. PubMed ID: 20707601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense technology to lower LDL cholesterol.
    Neely RD; Bassendine MF
    Lancet; 2010 Mar; 375(9719):959-61. PubMed ID: 20227757
    [No Abstract]   [Full Text] [Related]  

  • 5. [Controlling LDL cholesterol from 2 sides. "I have never seen such low LDL values"].
    MMW Fortschr Med; 2003 May; 145(20):59. PubMed ID: 12822234
    [No Abstract]   [Full Text] [Related]  

  • 6. Is mipomersen ready for clinical implementation? A transatlantic dilemma.
    Sjouke B; Balak DM; Beuers U; Ratziu V; Stroes ES
    Curr Opin Lipidol; 2013 Aug; 24(4):301-6. PubMed ID: 23759796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-lowering treatment for homozygous familial hypercholesterolaemia.
    Santos RD
    Lancet; 2013 Apr; 381(9873):1182. PubMed ID: 23561997
    [No Abstract]   [Full Text] [Related]  

  • 8. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
    Rader DJ; Kastelein JJ
    Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695
    [No Abstract]   [Full Text] [Related]  

  • 9. [LDL cholesterol--why lower and lower?].
    Müller-Wieland D; Kotzka J
    MMW Fortschr Med; 2007 May; 149(22):28-30. PubMed ID: 18069223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol absorption inhibitors in the treatment of hyperlipidemia: clinical outcomes in large clinical trials.
    Kesäniemi A
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():29-30. PubMed ID: 18001318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ENHANCE: food for the ostriches.
    Jackson G
    Int J Clin Pract; 2008 May; 62(5):667-8. PubMed ID: 18412925
    [No Abstract]   [Full Text] [Related]  

  • 12. [Lowering of LDL cholesterol prevents cardiovascular diseases. "Normal values" are too high--treatment time is a crucial factor].
    Rudling M
    Lakartidningen; 2006 Oct 25-31; 103(43):3278-82. PubMed ID: 17117659
    [No Abstract]   [Full Text] [Related]  

  • 13. Plant stanols do not restore endothelial function in pre-pubertal children with familial hypercholesterolemia despite reduction of low-density lipoprotein cholesterol levels.
    Jakulj L; Vissers MN; Rodenburg J; Wiegman A; Trip MD; Kastelein JJ
    J Pediatr; 2006 Apr; 148(4):495-500. PubMed ID: 16647412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial hypercholesterolemia: current treatment and advances in management.
    Huijgen R; Vissers MN; Defesche JC; Lansberg PJ; Kastelein JJ; Hutten BA
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):567-81. PubMed ID: 18402545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [60% of patients with coronary disease receive antilipemic drugs. Nevertheless cholesterol often is too high].
    MMW Fortschr Med; 2001 Nov; 143(44):60. PubMed ID: 11732408
    [No Abstract]   [Full Text] [Related]  

  • 18. Is there a problem with ezetimibe or just ENHANCEd hype?
    Whayne TF
    Angiology; 2008 Dec-2009 Jan; 59(6):661-3. PubMed ID: 18796445
    [No Abstract]   [Full Text] [Related]  

  • 19. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia.
    Miltiadous G; Saougos V; Cariolou M; Elisaf MS
    Ann Clin Lab Sci; 2006; 36(3):353-5. PubMed ID: 16951279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.